ENTA vs IRD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ENTA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. Most alarming is the negative gross margin of -117.05%, meaning the company loses money on every unit of revenue generated before operating expenses. Despite a speculative 654.9% price surge over the last year and a 'strong_buy' analyst consensus, the underlying data shows declining revenue (-10.20%) and extreme valuation multiples (P/B of 24.36). The stock appears to be trading on momentum or speculative expectations rather than any tangible financial health.
Compare Another Pair
Related Comparisons
ENTA vs IRD: Head-to-Head Comparison
This page compares Enanta Pharmaceuticals, Inc. (ENTA) and Opus Genetics, Inc. (IRD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.